Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Arman Nadershahi
AddedMar 31, 2024
UpdatedMay 31, 2026
Arman Nadershahi

Arman Nadershahi

Co-Founder, Protea

CrunchbaseLinkedIn

Arman Nadershahi's Career

Protea
Protea

Santa Monica, CA, US

Co-Founder
Proa Medical
Proa Medical

Redondo Beach, CA, US

Co-Founder
Varocto
Varocto

Los Angeles, CA, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Arman Nadershahi's Career

Protea
Protea
Seed$225k112020Santa Monica, CA, US
Co-Founder

Leadership at Protea

Jimena Gastelum GlenderJimena Gastelum GlenderCo-Founder

Similar to Protea

ZebelZebelWalnut Creek, CA, USData Analytics, Softwareest. 2019ZebelWalnut Creek, CA, US · est. 2019

Zebel Software: Accelerating real estate project feasibility with data-driven cost estimates and ROI analysis.

Pre-Seed · $50k11
REdevlyREdevlyPortland, OR, USReal Estate Softwareest. 2020REdevlyPortland, OR, US · est. 2020

REdevly: Streamlining real-estate development with accessible information and simplified planning tools.

Angel · $10k3
ProphiaProphiaSan Francisco, CA, USData Management, Lease Abstractionest. 2018ProphiaSan Francisco, CA, US · est. 2018

Prophia offers leading AI technology for lease abstraction and CRE data management, empowering landlords with real-time data.

Series A · $15.3M40
ProperProperSan Francisco, CA, USAccounting, Property Managementest. 2017ProperSan Francisco, CA, US · est. 2017

Proper: Automated accounting startup using AI and expert finance specialists to empower property managers.

Series B · $32.8M175
Proa Medical
Proa Medical
Pre-Seed$2.8M22010Redondo Beach, CA, US
Co-Founder

Leadership at Proa Medical

Sudeep DeshpandeSudeep DeshpandeCo-Founder
Michel KerdilesMichel KerdilesCEO

Similar to Proa Medical

Prospex MedicalProspex MedicalStillwater, MN, USMedical Devicesest. 2004Prospex MedicalStillwater, MN, US · est. 2004

Prospex Medical: Innovating in medical device design, research collaboration, and proof of concept.

Seed · $3M6
Advanced Medical Device TechnologiesAdvanced Medical Device TechnologiesNewport Beach, CA, USMedical Devicesest. 2019Advanced Medical Device TechnologiesNewport Beach, CA, US · est. 2019

Advanced Medical Device Technologies: Your trusted provider of innovative medical device designs.

Seed · $250k2
ExploraMed NC7ExploraMed NC7Mountain View, CA, USMedical Devicesest. 2014ExploraMed NC7Mountain View, CA, US · est. 2014

ExploraMed, a US-based medical tech incubator, accelerates the creation of innovative medical devices, meeting global health needs.

Series C · $132.6M30
Piraeus MedicalPiraeus MedicalRochester, MN, USMedical Devicesest. 2021Piraeus MedicalRochester, MN, US · est. 2021

Piraeus Medical: A stealth-mode healthcare company creating devices for enhanced patient care.

Seed · $3.1k6
Varocto
Varocto
Series A$5.5M72014Los Angeles, CA, US
Co-Founder

Leadership at Varocto

Scott FraserScott FraserCo-Founder
Winn HongWinn HongCEO

Similar to Varocto

VohtrVohtrStaunton, VA, USAnalytics, Dataest. 2014VohtrStaunton, VA, US · est. 2014

Vohtr: Real-time opinion data provider for informed decision-making via tablets and mobile apps.

Seed · $905k1
Vero AnalyticsVero AnalyticsVienna, VA, USData Analyticsest. 2014Vero AnalyticsVienna, VA, US · est. 2014

Vero: Simplifying data analysis and visualization, enabling effortless collaboration on metrics.

Seed · $550k1
VoythosVoythosHouston, TX, USMedical Softwareest. 2020VoythosHouston, TX, US · est. 2020

Texas-based Voythos develops digital tools for healthcare workers to manage medical records efficiently.

Pre-Seed · $100k1
Visus TherapeuticsVisus TherapeuticsSeattle, WA, USEye Dropsest. 2019Visus TherapeuticsSeattle, WA, US · est. 2019

Visus Therapeutics: Pioneering presbyopia-correcting eye drops with 8-hour potential.

Series B · $56M45

People Similar to Arman Nadershahi

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · KakaoRobert ThomasRobert ThomasBoard Member · AcretoNeil CallahanNeil CallahanCo-Founder & CEO · Pilot Growth EquityJames SmithJames SmithBoard Member · HypresJohn LaramieJohn LaramieCo-Founder & CEO · ADstrucMichael YangMichael YangBoard Member · Kiwi CrateRyan RussellRyan RussellCo-Founder · Avenue Growth Partners